Brolucizumab
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM) . Brolucizumab can be used for the research of cancer[1][2].
Product Specifications
CAS Number
1531589-13-5
Product Name Alternative
DLX1008; ESBA 1008; RTH258
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brolucizumab.html
Purity
99.90
Solubility
H2O
Smiles
[Brolucizumab]
Molecular Weight
(26.18 kDa)
References & Citations
[1]Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365 (2) :422-429.|[2]Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15 (5) :e0233116.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP20956PU-N 100 µg
MEK1 (MAP2K1) pSer218 Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
BNC680801-100 1x 100 µL
PSA (Prostate Specific Antigen) (KLK3/801), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
